Publications by authors named "E I Surace"

Gene expression emerges from DNA sequences through the interaction of transcription factors (TFs) with DNA cis-regulatory sequences. In eukaryotes, TFs bind to transcription factor binding sites (TFBSs) with differential affinities, enabling cell-specific gene expression. In this view, DNA enables TF binding along a continuum ranging from low to high affinity depending on its sequence composition; however, it is not known whether evolution has entailed a further level of entanglement between DNA-protein interaction.

View Article and Find Full Text PDF

The Alzheimer's Disease Neuroimaging Initiative (ADNI) has fostered collaboration among researchers around the world, catalyzing innovation and accelerating progress in the field. In Latin America, this initiative advanced the validation and development of Alzheimer's disease biomarkers for the first time in our region. In 2011, as part of the international ADNI, Argentina-ADNI (Arg-ADNI) was founded.

View Article and Find Full Text PDF

In this high-throughput proteomic study of autosomal dominant Alzheimer's disease (ADAD), we sought to identify early biomarkers in cerebrospinal fluid (CSF) for disease monitoring and treatment strategies. We examined CSF proteins in 286 mutation carriers (MCs) and 177 non-carriers (NCs). The developed multi-layer regression model distinguished proteins with different pseudo-trajectories between these groups.

View Article and Find Full Text PDF
Article Synopsis
  • - The study focused on understanding early changes in cerebrospinal fluid (CSF) proteins in individuals with Autosomal Dominant Alzheimer's disease (ADAD), identifying 125 proteins that exhibit different patterns between mutation carriers and non-carriers.
  • - Researchers used advanced methods like the Somascan® 7K assay and machine learning to reveal that 12 of these proteins change before traditional Alzheimer's biomarkers, potentially serving as early indicators of the disease.
  • - The identified proteins were categorized into three stages linked to disease progression, providing insight into biological processes occurring years before clinical symptoms, which may help in developing monitoring strategies and treatments.
View Article and Find Full Text PDF

Approximately 5% of Alzheimer's disease cases have an early age at onset (<65 years), with 5-10% of these cases attributed to dominantly inherited mutations and the remainder considered as sporadic. The extent to which dominantly inherited and sporadic early-onset Alzheimer's disease overlap is unknown. In this study, we explored the clinical, cognitive and biomarker profiles of early-onset Alzheimer's disease, focusing on commonalities and distinctions between dominantly inherited and sporadic cases.

View Article and Find Full Text PDF